TGTX

TG Therapeutics (TGTX)

About TG Therapeutics (TGTX)

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

Details

Daily high

$31.59

Daily low

$30.40

Price at open

52 Week High

$46.48

52 Week Low

$25.28

Market cap

5.0B

Dividend yield

0.00%

Volume

1.4M

Avg. volume

1.6M

P/E ratio

11.31

TG Therapeutics News